drugset / Trial / NCT00651378
Switching to Rosuvastatin Versus Adding Ezetimibe to Atorvastatin Versus Doubling the Dose of Atorvastatin in Patients With Hypercholesterolemia and Risk Factors (P03708)
RandomizedParallel-groupOpen-labelTreatment
Summary
This study assesses whether adding ezetimibe 10 mg/d to ongoing treatment with atorvastatin 10 mg/d is more effective than switching the subject to treatment with rosuvastatin 10 mg/d or doubling the dose of atorvastatin to 20 mg/d is more effective in achieving goal LDL-cholesterol of \<2.5 mmol/L. Treatment phase is 6 weeks.
Timeline
- Start
- 2004-09-01
- Primary completion
- 2005-06-01
- Completion
- 2005-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Atorvastatin | Small molecule | 10 mg | Oral |
| Comparator | Atorvastatin | Small molecule | 20 mg | Oral |
| Comparator | Ezetimibe | Unknown | 10 mg | Oral |
| Subject | Rosuvastatin | Small molecule | 10 mg | Oral |